Company profile
iQure Australia Pty Ltd (iQure Pharma Inc.)
Privately held: no public share price (Not on the roster. Australian entity of iQure Pharma Inc. (US-registered, Wilmington/Princeton), developing iQ-007 for drug-resistant epilepsy (NCT06899230). Privately held, funded by Ventura BioMed Investors and OKG Capital (2023 round); no stock listing. Distinct from "uniQure Biopharma B.V." (row 22) despite the name-substring overlap. Sources: https://clinicaltrials.gov/study/NCT06899230 ; https://www.iqurepharma.com/ ; https://www.biospace.com/iqure-pharma-secures-funding-from-ventura-biomed-investors-and-okg-capital Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | EAAT2 (glutamate transporter, positive allosteric modulator)Small molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.